TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ULTANE

SEVOFLURANE
Respiratory Approved 1995-06-07
2
Indications
--
Phase 3 Trials
30
Years on Market

Details

Status
Prescription
First Approved
1995-06-07
Routes
INHALATION
Dosage Forms
LIQUID

Companies

Active Ingredient: SEVOFLURANE

ULTANE Approval History

Loading approval history...

What ULTANE Treats

2 FDA approvals

Originally approved for its first indication in 1995 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ULTANE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

ULTANE is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. ULTANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.